Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03872947 · ClinicalTrials.gov registry record · Phase 1

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

A Phase 1 study of Colorectal Cancer and Ovarian Cancer, sponsored by Toray Industries.

Active
Registry status
Phase 1
Development phase
138
Enrollment target
14
Study locations

NCT03872947: Active Phase 1 study of Colorectal Cancer and Ovarian Cancer, sponsored by Toray Industries.

NCT03872947 is a Phase 1 study of Colorectal Cancer and Ovarian Cancer that is active but no longer recruiting, run by Toray Industries. The registered enrollment target is 138 participants, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (91% lower). The trial reports 14 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03872947, a Phase 1 study of Colorectal Cancer and Ovarian Cancer, is active but no longer recruiting, sponsored by Toray Industries.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
138 participants
Enrollment target
14
Study locations

Study Summary

The main purpose of this study is to establish the safety and the recommended dose of TRK-950 in combination with FOLFIRI, Gemcitabine / Cisplatin, Gemcitabine / Carboplatin, Ramucirumab / Paclitaxel, PD1 inhibitors (Nivolumab or Pembrolizumab), and Imiquimod Cream, Bevacizumab, Gemcitabine / Carboplatin / Bevacizumab, Pegylated liposomal doxorubicin (PLD), Carboplatin / PLD / Bevacizumab and Paclitaxel for selected advanced solid tumors.

Conditions Studied

Colorectal Cancer Ovarian Cancer Melanoma Solid Tumor Bladder Cancer Gastric Cancer Renal Cell Carcinoma Cholangiocarcinoma Epithelial Ovarian Cancer Palpable Subcutaneous Malignant Lesions

Interventions

  • DRUG Leucovorin
  • DRUG Irinotecan
  • BIOLOGICAL TRK-950

Study Locations (14)

Arizona

  • HonorHealth Research Institute - Scottsdale
  • AOA-HOPE - Tucson

California

  • USC Norris Comprehensive Cancer Center - Los Angeles
  • HOAG Memorial Hospital Presbyterian - Newport

Oregon

  • Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute and Research Center) - Eugene
  • Northwest Cancer Specialists - Portland

Texas

  • Texas Oncology, P.A. Baylor Charles A. Sammons Cancer Center - Dallas
  • Texas Oncology - Downtown Fort Worth Cancer Center - Fort Worth

Louisiana

  • Ochsner Clinic Foundation - New Orleans

New Jersey

  • Atlantic Health System - Morristown

New York

  • Perlmutter Cancer Center at NYU Langone - New York

Virginia

  • Virginia Cancer Specialists, PC - Leesburg

Trial Details

FieldValue
Enrollment Target 138 participants
Start Date 2019-04-26
Est. Completion 2026-06
Phase Phase 1
Toray Industries

5 total trials

What the registry record for NCT03872947 still lists

NCT03872947 is an interventional study that assigns participants to a tested intervention. The registered 138 participants enrollment target is mid-sized for trials with a published cap, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (91% lower).

The record links to 10 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 3 interventions - of which Leucovorin is the first listed.

NCT03872947 lists 14 locations in 10 states (Arizona, California, Oregon).

Frequently Asked Questions

What is clinical trial NCT03872947 about?

NCT03872947 is a clinical study titled "A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors". The main purpose of this study is to establish the safety and the recommended dose of TRK-950 in combination with FOLFIRI, Gemcitabine / Cisplatin, Gemcitabine / Carboplatin, Ramucirumab / Paclitaxel, PD1 inhibitors (Nivolumab or Pembrolizumab), and Imiquimod Cream, Bevacizumab, Gemcitabine / Carbop...

What is the current status of trial NCT03872947?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 138 participants. The study started on 2019-04-26. Estimated completion is 2026-06.

What conditions does trial NCT03872947 study?

This clinical trial studies the following conditions: Colorectal Cancer, Ovarian Cancer, Melanoma, Solid Tumor, Bladder Cancer.

What interventions are being tested in trial NCT03872947?

The interventions under investigation include: Leucovorin (DRUG), Irinotecan (DRUG), TRK-950 (BIOLOGICAL).

Who is sponsoring clinical trial NCT03872947?

This trial is sponsored by Toray Industries, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03872947 being conducted?

This trial has 14 study locations across Arizona, California, Louisiana, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Colorectal Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03872947's enrollment target sits among peer trials

138 180th of 381 higher than 200 of 381 other Colorectal Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04402788 · 138 participants · Phase 2

    Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

  • NCT04883255 · 138 participants · Early Phase 1

    Cannabis Use, Cognition, and the Endocannabinoid System in HIV

  • NCT05620784 · 138 participants · Phase 3

    Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP

  • NCT05832086 · 138 participants · Phase 2

    Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT03872947, the US trial registry maintained by the National Library of Medicine. NCT03872947 (mid enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.